Company Overview of Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc. is engaged in the discovery, development, and commercialization of treatments and therapies for rare and orphan diseases. The company’s lead product candidate includes pharmaceutical-grade L-glutamine, which has completed Phase III clinical trials for the treatment of sickle cell disease. It also markets and sells NutreStore, an L-glutamine powder for oral solution as a treatment for short bowel syndrome in patients receiving specialized nutritional support; and sells L-glutamine as a nutritional supplement under the AminoPure brand name through retail stores in various states, as well as through importers and distributors in Japan, Taiwan, and South Korea. The com...
20725 South Western Avenue
Torrance, CA 90501
Founded in 2000
Key Executives for Emmaus Life Sciences, Inc.
Chief Financial Officer and Executive Vice President
Senior Vice President of Finance
Senior Vice President of Research and Development
Compensation as of Fiscal Year 2014.
Emmaus Life Sciences, Inc. Key Developments
Emmaus Life Sciences, Inc. Announces Resignation of Duane Kurisu to the Board of Directors
Jan 15 15
On January 9, 2015, Emmaus Life Sciences, Inc. received notice from Mr. Duane Kurisu of his resignation from the Board of Directors of the company. Mr. Kurisu's resignation was not due to any disagreement with the Company and, in accordance with the Company's By-laws, was effective on January 9, 2015.
Emmaus Life Sciences, Inc., Annual General Meeting, Oct 23, 2014
Sep 19 14
Emmaus Life Sciences, Inc., Annual General Meeting, Oct 23, 2014., at 09:00 Pacific Standard Time. Location: DoubleTree Hotel located at 21333 Hawthorne Blvd.. Agenda: To elect the directors named in the accompanying Proxy Statement to hold office until the 2015 Annual Meeting of Stockholders; to ratify the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2014; to conduct a non-binding advisory vote on its 2013 executive compensation; to ratify a recent amendment to 2011 Stock Incentive Plan; and to transact such other business as may properly come before the Annual Meeting and any adjournment or postponement thereof.
Emmaus Life Sciences, Inc. Announces Board Appointments
May 22 14
Emmaus Life Sciences, Inc. announced the appointment of four new members to its Board of Directors: Duane Kurisu, Chairman and CEO of Aio; Moni Miyashita, Senior Advisor with a global consulting firm and former IBM Vice President, Corporate Development; Phillip Satow, Chairman of the Board of JDS Therapeutics and co-Founder and former CEO of JDS Pharmaceuticals; and Mayu Sris, Founding Partner and Managing Director of Sarissa Capital Management. Mr. Kurisu, Ms. Miyashita, Mr. Satow and Mr. Sris join Emmaus' independent directors, Tracey Doi, Chief Financial Officer of Toyota Motor Sales, U.S.A., and Dr. Henry McKinnell, Chairman of the Board of Moody's Corporation and former Chairman and CEO of Pfizer. Ms. Miyashita is an independent advisor on mergers and acquisitions at a global consulting firm. She previously held a more than 30 year career at IBM, where she served as Vice President, Corporate Development. Mr. Satow is currently Chairman of the Board of Directors of JDS Therapeutics, LLC. Mr. Sris is a Founding Partner and Managing Director of Sarissa Capital Management LP. He most recently served as an Investment Analyst at Icahn Capital, 2005 to 2010 and as a consultant in 2011, where he contributed to all aspects of the activist investing process with the goal of proactively creating substantial value.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 12, 2014